A Cardinal Health report reviewed the potential impact biosimilars will have in rheumatology, gastroenterology, dermatology, and ophthalmology.
While 2022 might have been a turning point for biosimilars, 2023 is expected to bring more disruption, according to a new report from Cardinal Health. The 2023 Biosimilars Report1 reviewed the potential impact biosimilars will have in rheumatology, gastroenterology, dermatology, and ophthalmology, and analyzed data on biosimilar utilization, government pricing reform, and payer coverage.
The report surveyed 350 providers and provided an analysis of how the market may be affected with as many as 10 adalimumab biosimilars launching in 2023. Currently, there are 8 FDA-approved adalimumab biosimilars. The first, Amjevita, has already launched and will have market exclusivity for 6 months.
Although biosimilars may have had a slow start in the United States, they have become an important tool to drive substantial cost savings for some of the most expensive biologics on the market, Bruce Feinberg, DO, vice president and chief medical officer, Cardinal Health, wrote in the report.
"Biosimilars bring competition and lower costs to patient-critical treatments," he said in a statement.2 "In order to deliver on the promise of these drugs from a health equity standpoint, we must continue to analyze prescriber awareness and familiarity. Through our research, Cardinal Health seeks to understand prescribers' perceptions and what other factors are moving the industry forward—from business and financial decisions to provider adoption."
The report noted a growing familiarity of biosimilars among rheumatologists, with 76% now saying they are very familiar with these products compared with 56% in a report released June 2022. Only gastroenterologists reported being more familiar, with 81% saying they were very familiar with biosimilars. Ophthalmologists and dermatologists were much farther behind, with only 33% and 31%, respectively, saying they were very familiar.
Gastroenterologists reported that they needed the smallest discount on price to be motivated to switch to a biosimilar. Forty percent said they only needed a discount of 30% or less from the reference product, while 36% of ophthalmologists said they needed a discount greater than 40%. However, dermatologists were the most likely (20%) to say no discount would motivate them to prescribe the biosimilar over a reference product.
The first ranibizumab biosimilar in ophthalmology launched July 2022 at a 40% discount to the reference product. More than half (58%) said the 40% discount made them more likely to prescribe the biosimilar Byooviz over the reference product Lucentis. However, 31% said the discount had no impact and 11% said it made them less likely to prescribe the biosimilar. A second ranibizumab biosimilar launched in October 2022 with the interchangeability designation.
“While it is still too early to tell as of this writing how the early launches have fared from an adoption standpoint, we expect share shifts in the ophthalmology market to evolve more slowly as our market research data reveals significant provider hesitation with biosimilars remains,” the Cardinal Health report noted.
When it came to prescribing decisions:
All dermatologists, rheumatologists, and gastroenterologists were asked about adalimumab biosimilars. By specialty, the top concerns regarding adalimumab were:
All specialties cited clinical and/or real-world evidence studies as key decision criteria for utilizing an adalimumab biosimilar. Real-world evidence, either gathered internationally or domestically, was cited as the best way to support clinical confidence to utilize adalimumab biosimilars in both new and existing patients eligible for adalimumab.
“These findings further highlight the continued need for education to strengthen clinical confidence in these agents and help overcome key barriers to a more robust biosimilars market in the US,” according to the report.
References
1. 2023 biosimilas report. Cardinal Health. Accessed February 24, 2023. https://www.cardinalhealth.com/en/product-solutions/pharmaceutical-products/biosimilars/biosimilars-report.html
2. New Cardinal Health report examines shifts in biosimilars industry. News release. Cardinal Health. February 22, 2023. Accessed February 24, 2023. https://newsroom.cardinalhealth.com/2023-02-22-New-Cardinal-Health-report-examines-shifts-in-biosimilars-industry
Study Highlights Significant Increases in Utilization, Spending on DMD Drugs in Medicaid
May 17th 2024The findings add to recent research on the growing utilization, expenditure, and prices of Duchenne muscular dystrophy (DMD) therapies in the current landscape, an area health care policy could potentially address.
Read More
Frameworks for Advancing Health Equity: Urban Health Outreach
May 9th 2024In the series debut episode of "Frameworks for Advancing Health Equity," Mary Sligh, CRNP, and Chelsea Chappars, of Allegheny Health Network, explain how the Urban Health Outreach program aims to improve health equity for individuals experiencing homelessness.
Listen
Panel Addresses Minority Physician Shortage, Maternal Health at Senate Committee Hearing
May 15th 2024The senate hearing held by the US Senate Committee on Health, Education, Labor, and Pensions, led by Sen. Bernie Sanders (I, Vermont), chairman of the committee, and ranking member Sen. Bill Cassidy, MD, (R, Louisiana), addressed the critical issue of physician and health care worker shortages, as well as the maternal health crisis, in the US.
Read More
Tackling Health Inequality: The Power of Education and Experience
April 30th 2024To help celebrate and recognize National Minority Health Month, we are bringing you a special month-long podcast series with our Strategic Alliance Partner, UPMC Health Plan. Welcome to our final episode of this limited series and our conversation with Janine Jelks-Seale, MSPPM, director of health equity at UPMC Health Plan.
Listen
Bleeds and Resource Use in Hemophilia B: Retrospective Observational Study
May 15th 2024This real-world US study describes individuals with hemophilia B who experience bleeds despite factor replacement therapy and quantifies the associated comorbidity and health care resource utilization burden.
Read More
A new study highlights significant disparity in reimbursement rates across states between hospitals and Medicare; the first patient to receive a genetically modified pig kidney has died; research examines outcomes of over 500 patients receiving medication abortion pills by mail.
Read More